A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

DAREON-9: A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with topotecan for the treatment of patients with

A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors

A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma